SYSTEMATIC REVIEW
Accepted on 07 Aug 2025
Dual-target Immunotherapies in NSCLC: A Systematic Review and Meta-analysis of Randomized Clinical Trials
doi 10.3389/fimmu.2025.1605877
- 140 views
- Frontiers in Immunology
- Cancer Immunity and Immunotherapy
- Research Topics
- Bispecific Antibodies and their Conjugates in Solid Tumors and Hematological Malignancies
Bispecific Antibodies and their Conjugates in Solid Tumors and Hematological Malignancies
3,228
Total downloads
17k
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
ORIGINAL RESEARCH
Accepted on 04 Aug 2025
Trispecific eFab-eIg T-cell engagers targeting HER2 and HER3
doi 10.3389/fimmu.2025.1642454
- 530 views
ORIGINAL RESEARCH
Accepted on 24 Jul 2025
Dual T/NK Cell Engagement via B7-H6-Targeted Bispecific Antibodies and IL-15 Eradicates Chemo-Resistant Solid Tumors
doi 10.3389/fimmu.2025.1625813
- 193 views
REVIEW
Published on 23 Jul 2025
Blinatumomab in pediatric B-acute lymphoblastic leukemia
doi 10.3389/fimmu.2025.1611701
- 1,101 views
CORRECTION
Published on 17 Jul 2025
Correction: Bispecific antibody for lung cancer: mechanisms and clinical insights
doi 10.3389/fimmu.2025.1656082
- 274 views
ORIGINAL RESEARCH
Published on 18 Jun 2025
Characterization and functional evaluation of JS207, a novel bispecific antibody against human PD-1 and VEGFA
doi 10.3389/fimmu.2025.1612547
- 2,820 views
REVIEW
Published on 29 May 2025
Bispecific antibody for lung cancer: mechanisms and clinical insights
doi 10.3389/fimmu.2025.1572802
- 1,859 views
SYSTEMATIC REVIEW
Published on 25 Apr 2025
Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis
doi 10.3389/fimmu.2025.1565407
- 3,079 views
MINI REVIEW
Published on 09 Apr 2025
Bispecific antibodies in immunotherapy for acute leukemia: latest updates from the 66th annual meeting of the American society of hematology, 2024
doi 10.3389/fonc.2025.1566202
- 1,850 views
CASE REPORT
Published on 31 Mar 2025
Successful treatment of primary refractory DLBCL/HGBL - MYC/BCL2 transformed from FL using glofitamab: a case report
doi 10.3389/fimmu.2025.1566035
- 1,822 views
- 1 citation
Published in
Frontiers in Immunology
Cancer Immunity and Immunotherapy
Participating Journals
Frontiers in Oncology
- 3.3 impact factor
- 6.9 citescore
Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.
Submit your idea
Select the journal/section where you want your idea to be submitted: